What can one dose of #immunotherapy achieve? In localized dMMR #coloncancer, a single dose of neoadjuvant pembrolizumab led to significant pathological complete responses (pCR) in 61% of Stage I-II patients. Game-changing potential! 🔬✨ #GI25 #cancerresearch @ASCO